Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
3.1. Market Snippet by Enzyme Type
3.2. Market Snippet by Indication Type
3.3. Market Snippet by Route of Administration
3.4. Market Snippet by End-Users
3.5. Market Snippet by Region
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. High healthcare spending on rare diseases
4.1.1.2. Rising prevalence of rare diseases
4.1.2. Restraints:
4.1.2.1. Lack of skilled professional
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Value Chain Analysis
5.4. PEST Analysis
5.5. Pricing Analysis
5.6. Regulatory Analysis
5.7. Reimbursement Analysis
5.8. Unmet Needs
5.9. Patent Trends
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Enzyme Type
7.1. Introduction
7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Enzyme Type Segment
7.3. Market Attractiveness Index, By Enzyme Type Segment
7.3.1. Alglucerase alfa*
7.3.1.1. Introduction
7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
7.3.2. Imiglucerase
7.3.3. Taliglucerase alfa
7.3.4. Velaglucerase alfa
8. By Indication Type
8.1. Introduction
8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type Segment
8.3. Market Attractiveness Index, By Indication Type Segment
8.3.1. Gaucher Disease*
8.3.1.1. Introduction
8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
8.3.2. Fabry Disease
8.3.3. Pompe Disease
8.3.4. Hurler Syndrome
8.3.5. Others
9. By Route of Administration
9.1. Introduction
9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
9.3. Market Attractiveness Index, By Route of Administration
9.3.1. Oral*
9.3.1.1. Introduction
9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
9.3.2. Injectable
10. By End-Users
10.1. Introduction
10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users
10.1.2. Market Attractiveness Index, By End-Users
10.2. Hospitals & Clinics*
10.2.1. Introduction
10.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
10.3. Homecare
10.4. Others
11. By Region
11.1. Introduction
11.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
11.3. Market Attractiveness Index, By Region
11.4. North America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Enzyme Type
11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users
11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. U.S.
11.4.7.2. Canada
11.4.7.3. Mexico
11.5. Europe
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Enzyme Type
11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users
11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. Germany
11.5.7.2. U.K.
11.5.7.3. France
11.5.7.4. Italy
11.5.7.5. Spain
11.5.7.6. Rest of Europe
11.6. South America
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Enzyme Type
11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users
11.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.6.7.1. Brazil
11.6.7.2. Argentina
11.6.7.3. Rest of South America
11.7. Asia Pacific
11.7.1. Introduction
11.7.2. Key Region-Specific Dynamics
11.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Enzyme Type
11.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
11.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
11.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users
11.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.7.7.1. China
11.7.7.2. India
11.7.7.3. Japan
11.7.7.4. Australia
11.7.7.5. Rest of Asia Pacific
11.8. Middle East and Africa
11.8.1. Introduction
11.8.2. Key Region-Specific Dynamics
11.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Enzyme Type
11.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
11.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
11.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users
11.8.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. AbbVie PLC*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Key Highlights
13.1.4. Financial Overview
13.2. Alexion Pharmaceuticals Inc.
13.3. Allergan plc
13.4. BioMarin Pharmaceutical Inc.
13.5. Horizon Pharma Public Limited Company
13.6. Protalix Biotherapeutics
13.7. Recordati Rare Diseases
13.8. Johnson & Johnson Services Inc.
13.9. Sanofi SA
13.10. Shire PLC (List Not Exhaustive)
14. Premium Insights
15. DataM Intelligence
15.1. Appendix
15.2. About Us and Services
15.3. Contact Us